ICI-170809

ICI-170809, also known as ZM-170809, is a selective serotonin 5-HT 2 receptor antagonist which was under development for the treatment of major depressive disorder, arrhythmias, thrombosis, and ischemic heart disorders but was never…

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

ICI-170809, also known as ZM-170809, is a selective serotonin 5-HT 2 receptor antagonist which was under development for the treatment of major depressive disorder, arrhythmias, thrombosis, and ischemic heart disorders but was never marketed. It was being developed by AstraZeneca. The drug reached phase 2 clinical trials prior to the discontinuation of its development.

See also

List of investigational antidepressants

Text derived from https://en.wikipedia.org/w/index.php?oldid=1328696130 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.